CSL Behring said on December 5 that it initiated a nationwide home delivery service for Berinert SC Injection (human C1 inactivator), a prophylactic treatment for acute hereditary angioedema (HAE) attacks, on December 1. The company's “CSL Home Delivery” service delivers…
To read the full story
Related Article
- CSL Launches Original Home Delivery Service for Hizentra
November 8, 2023
- CSL/Alfresa Roll Out Home Delivery Service of Hemophilia Drugs
October 4, 2023
- CSL Behring Soon to Launch Home Delivery Service for Hemophilia Therapies
February 8, 2023
BUSINESS
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
- Enhertu Combo Wins US FDA Nod in 1st-Line HER2 Breast Cancer
December 17, 2025
- Pfizer Releases Nurtec Migraine Drug in Japan
December 17, 2025
- Towa Lifts Atomoxetine Shipment Curbs Across All Strengths
December 17, 2025
- Daiichi Sankyo Targets Cancer Cure with IO-ADC Combo Strategy
December 17, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





